Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBI-833/OBI-821 Maintenance in Advanced Biliary Tract Cancer
NCT06490198Phase 1Not yet recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of OBI-833 in biliary tract cancer (BTC), sponsored by Chang Gung Memorial Hospital. Primary endpoint: Progression-Free Survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
OBI-833
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06490198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490198.